蒂尔泽帕提德滴:小心瘦身者的
John M Tucker1, Jordan Ritchie1
1Medical University of South Carolina, Charleston, USA.
概括
提尔泽帕提德辅助的减肥可能会导致脚,这种情况被称为瘦身者. 这一案例系列强调了在快速减肥疗法期间监测患者神经复杂症的重要性.
科学领域:
- 神经学 神经学
- 内分泌学 在内分泌学.
- 代谢障碍 代谢障碍 代谢障碍
背景情况:
- 提尔泽帕提德是一种有效的减肥药.
- 快速减肥可能与各种并发症有关.
- 经管神经神经病变,或脚掉落,是一个潜在的风险.
研究的目的:
- 探索提尔泽帕提德诱导的体重减轻和脚的发展之间的关联.
- 为了研究在接受蒂尔泽帕提德治疗的患者中出现的"瘦身者"现象.
- 提高医疗保健提供者对潜在神经系统副作用的认识.
主要方法:
- 案例系列方法.
- 介绍了两名患者的病例与蒂尔泽帕提德治疗.
- 对神经症状的临床评估,特别是脚下跌.
主要成果:
- 两名患者在开始服用蒂尔泽帕提德6至8个月后出现双边脚下降.
- 在这两位患者中都观察到快速减肥.
- 脚掉落的原因是经神经神经病变.
结论:
- 提尔泽帕提德辅助的减肥可能与腹腔神经神经病变 (脚掉落) 的风险增加有关.
- 医疗保健提供者应密切监测患者在tirezepatide神经复杂症.
- "瘦身者"的可能性需要在快速减肥干预期间保持警的患者管理.
相关概念视频
Dipeptidyl Peptidase 4 Inhibitors
180
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
180
Glucagon-like Receptor Agonists
312
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
312
Oral Hypoglycemic Agents: Biguanides and Glitazones
186
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
186
Oral Hypoglycemic Agents: Glinides
151
Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively...
151
Drugs Affecting GI Tract Motility: Serotonin Receptor Agonists
239
Serotonin, a crucial neurotransmitter synthesized by enterochromaffin cells, plays a cardinal role in regulating gastrointestinal (GI) motility. With over 90% of the body's total serotonin in the GI tract, its influence on digestive processes is profound. Serotonin is swiftly released upon various stimuli, such as food boluses or certain drugs, triggering intrinsic sensory neurons in the myenteric plexus and extrinsic vagal and spinal sensory neurons. This leads to the activation of the...
239
Antiepileptic Drugs: Potassium Channel Activators
158
Ezocgabine or retigabine, an antiepileptic drug of remarkable efficacy, has revolutionized the management of seizures. It is a potassium channel activator, explicitly targeting the family of Q subtype potassium channels. It enhances the transmembrane potassium currents, regulating neuronal excitability. This action stabilizes the resting membrane potential, a pivotal factor in mitigating the hyperexcitability that characterizes epilepsy.
Ezogabine has gained approval as an adjunctive treatment...
Ezogabine has gained approval as an adjunctive treatment...
158


